Skip to content

Cyclosporine A in the treatment of unexplained recurrent abortion: a prospective, randomized, double-blind, superior efficacy, placebo-controlled, single-center trial

Cyclosporine A in the treatment of unexplained recurrent abortion: a prospective, randomized, double-blind, superior efficacy, placebo-controlled, single-center trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046724
Enrollment
Unknown
Registered
2021-05-27
Start date
2022-08-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent abortion of unknown cause

Interventions

The experimental group:Take cyclosporine oral solution
The control group:Take placebo

Sponsors

Taizhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 39 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-39 years, spontaneous abortion >= 3 times in the past; 2. Both spouses have no family genetic diseases and have normal chromosomal karyotypes; 3. Both spouses do not smoke; 4. The male semen analysis is normal; 5. The patient himself agrees to participate in this clinical study and signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Any infection, endocrine and anatomical abnormalities; 2. Acquire patients with thrombotic hemophilia; 3. The woman is positive for antiphospholipid antibodies or other autoantibodies; 4. Those who have tested positive for TORCH and other infectious diseases; 5. Severe heart, liver, and kidney dysfunction; 6. Those who have been vaccinated 3 months before being selected for the study; 7. Take other experimental drugs within 1 month before being selected for the study or are participating in other clinical studies; 8. Allergic to the taken medicine or its components; 9. The attending doctor believes that it is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
The opening of the cervix;

Secondary

MeasureTime frame
Blood HCG;Blood drug concentration;Autoantibodies;Pathogenic four;Th1;Th2;Th17;Treg;Blood coagulation function;Electrocardiogram;

Countries

China

Contacts

Public ContactGe Hongshan

Taizhou People's Hospital

dafeng76@126.com+86 18451687530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026